| 1 | our lead product pipeline | | | | | | | 2 | 0.82% |
| 2 | lead product pipeline newsmedia | | | | | | | 2 | 0.82% |
| 3 | product pipeline newsmedia contact | | | | | | | 2 | 0.82% |
| 4 | pipeline newsmedia contact us | | | | | | | 2 | 0.82% |
| 5 | company our lead product | | | | | | | 2 | 0.82% |
| 6 | home company our lead | | | | | | | 1 | 0.41% |
| 7 | biodegradable polymer system and | | | | | | | 1 | 0.41% |
| 8 | process development based on | | | | | | | 1 | 0.41% |
| 9 | development based on completely | | | | | | | 1 | 0.41% |
| 10 | based on completely synthetic | | | | | | | 1 | 0.41% |
| 11 | on completely synthetic no | | | | | | | 1 | 0.41% |
| 12 | completely synthetic no animal | | | | | | | 1 | 0.41% |
| 13 | synthetic no animal source | | | | | | | 1 | 0.41% |
| 14 | and hot melt extrusion | | | | | | | 1 | 0.41% |
| 15 | polymer system and hot | | | | | | | 1 | 0.41% |
| 16 | system and hot melt | | | | | | | 1 | 0.41% |
| 17 | copyright funded by seed | | | | | | | 1 | 0.41% |
| 18 | hot melt extrusion process | | | | | | | 1 | 0.41% |
| 19 | newsmedia contact legal privacy | | | | | | | 1 | 0.41% |
| 20 | literature newsmedia contact legal | | | | | | | 1 | 0.41% |
| 21 | scientific literature newsmedia contact | | | | | | | 1 | 0.41% |
| 22 | intellectual property preparations underway | | | | | | | 1 | 0.41% |
| 23 | property preparations underway to | | | | | | | 1 | 0.41% |
| 24 | policy copyright funded by | | | | | | | 1 | 0.41% |
| 25 | nervous system mainly the | | | | | | | 1 | 0.41% |
| 26 | mainly the brain cgmpcompliant | | | | | | | 1 | 0.41% |
| 27 | drug release at the | | | | | | | 1 | 0.41% |
| 28 | is based on proprietary | | | | | | | 1 | 0.41% |
| 29 | the bmwfw processed by | | | | | | | 1 | 0.41% |
| 30 | of the bmwfw processed | | | | | | | 1 | 0.41% |
| 31 | financing of the bmwfw | | | | | | | 1 | 0.41% |
| 32 | manufacturing process for tailored | | | | | | | 1 | 0.41% |
| 33 | process for tailored drug | | | | | | | 1 | 0.41% |
| 34 | for tailored drug release | | | | | | | 1 | 0.41% |
| 35 | tailored drug release at | | | | | | | 1 | 0.41% |
| 36 | release at the site | | | | | | | 1 | 0.41% |
| 37 | system mainly the brain | | | | | | | 1 | 0.41% |
| 38 | at the site of | | | | | | | 1 | 0.41% |
| 39 | the site of action | | | | | | | 1 | 0.41% |
| 40 | seed financing of the | | | | | | | 1 | 0.41% |